As key rate-limiting enzymes of the adenosinergic pathway, expressions of CD39 and CD73 will limit immune responses to inflammatory signals in the tumour microenvironment (TME), and affect the proliferation of tumours indirectly.74–76 However, the expression status of the two enzymes in TME is not the same. Here, ENTPD1 is linked to neoplasm.